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DESCRIPTION OF THE EVIDENCE COLLECTION METHOD
A search was conducted in EMBASE, SciELO/LILACS, 
PubMed/Medline, and Cochrane Library databases using 
the words: gastroesophageal reﬂux, GERD, heartburn, 
NERD, GERD, esophagus, esophagitis, extra-esophageal, 
asthma, atypical symptoms, chest pain, cough, globus 
sensations, hoarseness, otorhinolaryngologic diseases, 
pain, respiratory tract diseases, laryngitis, anti-ulcer 
agents, enzyme inhibitors, proton pumps, lansoprazole, 
omeprazole, proton pump inhibitors, rabeprazole, 
continuous, on-demand, surgery, fundoplication, non-
acid*, alkaline, weakly acid*, gas, stomach diseases, 
stomach/pathology, Helicobacter, Helicobacter infections, 
burimamide, imetidine, brotidine, etintidine, famotidine, 
lafutidine, loxtidine, metiamide, mifentidine, nizatidine, 
oxmetidine, ranitidine, ranitidine bismuth citrate, 
roxatidine acetate, tiotidine, zolantidine, histamine 
H2 antagonists, benzamides, dopamine antagonists, 
bromopride, domperidone, metoclopramide, smoking, 
alcohol, obesity, weight loss, caffeine, coffee, citrus, 
chocolate, spicy food, head of bed elevation, late-evening 
meal, diet*, life style, body mass index, alcoholic, 
postprandial period, eer, wine, supine position, food*, 
eating, exercise, dietary ﬁber, dietary fats, beds*, bedding 
and linens*. 
About 5,000 articles were retrieved, of which 87 
were selected to support this Guideline. The following 
ﬁlters were used: humans, randomized controlled trial, 
randomized AND controlled AND trial, clinical AND trial, 
clinical trials, random*, random allocation, therapeutic 
use, epidemiologic methods, cohort studies, cohort AND 
stud*, prognos*, ﬁrst AND episode, cohort. 
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DEGREE OF RECOMMENDATION AND STRENGTH OF EVIDENCE
A: Experimental or observational studies of higher 
consistency.
B: Experimental and observational studies of lower 
consistency.
C: Case reports (non-controlled studies).
D: Opinion without critical evaluation, based on con-
sensus, physiological studies, or animal models.
OBJECTIVES
Due to gastroesophageal reflux disease’s (GERD) high 
prevalence, variety in clinical presentation, economic im-
pact, consequences of impaired quality of life, and costs of 
clinical and laboratory research, international consensus 
meetings have been encouraged.
On the other hand, the diagnostic and therapeutic 
management of GERD has varied from center to center, 
which is an important factor in the search for scientific 
evidence on the subject and served as motivation for the 
development of this Guideline, which seeks to answer 12 
questions relevant to the clinical diagnosis of GERD.
1. WHAT IS THE CONTRIBUTION OF THE THERAPEUTIC 
TEST WITH PROTON PUMP INHIBITOR IN THE DIAGNOSIS OF 
PATIENTS WITH GERD?
Symptomatic response after four weeks of empirical treat-
ment with esomeprazole 40 mg (86.4%) in patients with 
GERD is similar to the treatment preceded by upper di-
gestive endoscopy (87.5%). Similarly, after maintenance 
treatment with esomeprazole 20 mg (24 weeks), a similar 
proportion of patients remained responders 71.8% versus 
68.3% (upper digestive endoscopy), respectively1(A).
The sensitivity test with rabeprazole 20 mg for 1-week 
compared to the diagnosis of GERD by upper digestive 
endoscopy and/or pH-metry has sensitivity of 83%, speci-
ficity of 45%, positive likelihood ratio of 1.5, and negative 
ratio of 0.37. Sensitivity, specificity, and positive and nega-
tive likelihood ratio of placebo were 40%, 67%, 1.2, and 
0.89, respectively2(A).
In patients with GERD (upper digestive endoscopy and 
pH-metry) and non-cardiac chest pain, the 4-week treat-
ment with lansoprazole 30 mg reduced the risk of persis-
tent symptoms in 59% (95% CI 2.3 to 201.8; NNT: 2). The 
sensitivity is 92%, specificity 67%, positive likelihood ratio 
of 2.78, and negative of 0.113(A).
In patients diagnosed with GERD by pH-metry and 
upper digestive endoscopy, the 4-week treatment sensitiv-
ity with esomeprazole 20 mg and 40 mg was 79% and 86%, 
respectively. The corresponding value for placebo is 36%. 
However, the specificity for treatment and placebo ranged 
from 24% to 65%. For the test with esomeprazole 20 mg, 
the positive and negative likelihood ratio ranged from 1.03 
to 2.25 and 0.8 to 0.32, respectively; and for esomeprazole 
40  mg, the positive and negative likelihood ratio ranged 
from 1.13 to 2.45 and 0.21 to 0.58, respectively4(A).
The test with omeprazole 40 mg in patients with GERD 
diagnosed by pH-metry has sensitivity of 68% and speci-
ficity of 63%, with positive and negative likelihood ratio of 
1.83 and 0.50, respectively5(A).
2. SHOULD GERD BE TREATED WITH FULL DOSE OF 
PROTON-PUMP INHIBITORS AND FOR EIGHT WEEKS?
ESOMEPRAZOLE
In patients with non-erosive GERD, night-time heartburn 
was treated in four weeks with outcomes of 53.1%, 50.5%, 
and 12.7% in patients receiving esomeprazole 40 mg, 20 mg, 
or placebo, respectively. The difference between esomepra-
zole 40 mg and 20 mg versus placebo was 40.5% (95% CI: 
32.4%, 48.5%) and 37.8% (95% CI: 29.9%, 45.7%), respec-
tively, with NNT of 2 in both treatments. Sleep disorders re-
lated to GERD were more significantly resolved in patients 
receiving esomeprazole 40  mg (73.7%) or 20  mg (73.2%) 
than in the placebo group (41.2%), with reduced risk of 
32.5% (NNT: 3) and 32.0% (NNT: 3), respectively6(A).
The 4-week treatment with esomeprazole 40  mg 
or 20  mg in patients with non-erosive GERD results 
in a risk reduction of heartburn, ranging from 18.8% 
(95% CI: 8.5-29.1) to 24.5% (95% CI: 14.0-35.0; NNT: 4 
or 5) with 40 mg, and from 20.2% (95% CI: 9.8-30.6) to 
29.7% (95% CI: 18.9-40.5; NNT: 3 or 5) with 20 mg7(A).
The overall result (erosive GERD: 240 and non-erosive: 
114) for response to treatment with esomeprazole 40 mg 
and 20 mg for a period of 12 days shows that the perma-
nence of heartburn was reduced in 38.1% (95% CI: 26.4-
49.8; NNT: 3) and in 40.3% (95% CI: 28.6-52.0; NNT: 2), 
respectively8(A).
LANSOPRAZOLE
Data on daily records of patients with non-erosive GERD 
indicate that after 8 weeks of treatment with lansoprazole 
30 mg or 15 mg the persistence of night-time heartburn 
was present in 49% and 39% of patients, respectively. 
Compared with placebo, there was reduced risk for 
the presence of night-time heartburn in 19.3% (95% CI: 
2.0- 36.6; NNT: 5) and 29.2% (95% CI: 11.9-46.5; NNT: 4), 
respectively. Similarly, daytime heartburn reduction with 
the use of 15 mg and 30 mg was 19.3% (95% CI: 3.6-35.0; 
NNT: 5) and 24.6% (95%  CI: 8.5-40.7; NNT: 4), respec-
tively 9(A).
OMEPRAZOLE
The healing rates in erosive GERD patients receiv-
ing omeprazole 40 mg and 20 mg for 4 weeks were 41% 
and 26%, with a difference of 15% (95%  CI: 2.5-27.3; 
NNT: 7)10(A).
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The reduction in risk of therapeutic failure with 
omeprazole 20  mg at 4 and 8 weeks is 53.2% (95%  CI: 
44.0-62.4; NNT: 2) and 46.2% (95%  CI: 36.5-55.9; 
NNT: 2)11(A).
The 4-week treatment of patients with non-erosive 
GERD receiving omeprazole 20  mg resulted in a re-
duced risk of persistent heartburn and dissatisfaction of 
33.0% (95%  CI: 23.6-42.4; NNT: 3) and 34.0% (95%  CI: 
23.9-45.9; NNT: 3), respectively. With the use of 
omeprazole 10  mg, the reduction was 17.9% (95%  CI: 
8.8-27.0; NNT: 6) and 25.9% (95% CI: 14.7-37.1; NNT 4), 
respectively12(A). 
PANTOPRAZOLE
The resolution rates of erosive esophagitis at 4 weeks 
were 55% and 72% with the use of pantoprazole 20  mg 
and 40  mg, respectively, compared to placebo that 
showed a reduced risk of esophagitis of 40.6% (95%  CI: 
30.0-51.2; NNT: 2) and 57.7% (95%  CI: 47.6-67.8; 
NNT: 2), respectively1(A). 
The reduced risk of erosive esophagitis at 8 weeks 
with the use of pantoprazole 20  mg and 40  mg was 
45.3% (95%  CI: 33.4-57.2; NNT: 2) and 55.5% (95%  CI: 
44.3-66.7; NNT: 2), respectively1(A).
Persistence of morning and daytime heartburn in 
patients treated with pantoprazole 40 mg at 8 weeks was 
21.0% and 18.0%, respectively; and risk reduction 
was 49.9% (95% CI: 38.3-61.5; NNT: 2) for morning and 
26.0% (95% CI: 13.8-38.2; NNT: 4) for nighttime13(A).
RABEPRAZOLE
In patients with GERD, the use of rabeprazole 20  mg 
for 4 weeks reduces the risk of persistent heartburn in 
28.6% (95%  CI: 18.9-38.3; NNT: 3) and regurgitation 
in 35.2% (95% CI: 21.7-48.7; NNT: 3)14(A).
The 4-week treatment in patients with non-erosive 
GERD receiving rabeprazole 10 mg or 20 mg produced a 
risk reduction of persistent heartburn in 25.2% (95%  CI: 
13.5-36.9; NNT: 4) and 25.5% (95% CI: 14.0-37.0; NNT: 4), 
respectively, and reduced the risk of dissatisfaction with the 
level of symptom improvement in 23.8% (95% CI: 7.3-40.3; 
NNT: 4) and 24.3% (95% CI: 8.0-40.6; NNT: 4)15(A).
RECOMMENDATIONS
In patients with non-erosive GERD, the use of esomepra-
zole at a dose of 40 mg for 4 weeks is more effective than a 
dose of 20 mg for the same period.
In patients with non-erosive GERD, the use of lanso-
prazole at a dose of 30  mg for 8 weeks is more effective 
than a dose of 15 mg for the same period.
The healing rates at 4-week treatment in patients with 
erosive GERD receiving omeprazole 40 mg are higher than 
in patients receiving 20 mg for the same period. In patients 
with non-erosive GERD, the use of omeprazole at a dose of 
20 mg is more effective than a dose of 10 mg, and 8-week 
treatment is more effective than 4-week treatment. 
In patients with erosive GERD, the use of pantoprazole 
at a dose of 40 mg is more effective than a dose of 20 mg, 
and 4-week and 8-week treatment are equivalent.
In patients with non-erosive GERD, the 4-week treat-
ment with rabeprazole at a dose of 20  mg or 10  mg is 
equivalent. 
3. ARE PROTON-PUMP INHIBITORS DIFFERENT IN GERD 
TERAPEUTIC RESPONSE?
ESOMEPRAZOLE (40 MG) VERSUS PANTOPRAZOLE (40 MG)
Pantoprazole and esomeprazole are equivalent in regard 
to improvement of symptoms (ReQuest-GI scale) during 
four weeks of treatment. The recurrence of symptoms af-
ter seven days of treatment (51% versus 61%; ARR: 10%; 
95%  CI: 1.1-18.9; NNT: 10) and the number symptom 
episodes (0.56 versus 0.74, p = 0.0095) were lower with 
esomeprazole than with pantoprazole16(A).
The number of patients cured (with improved esopha-
gitis) was higher with esomeprazole than with panto-
prazole in 4-week treatment (81% versus 75%; ARR: 6%; 
95%  CI: 3.1-8.9; NNT: 17) and 8-week treatment (96% 
versus 92%; ARR: 4%; 95% CI: 2.3-5.7; NNT: 25)17(A).
After 10 weeks of treatment, there is equivalence in the 
improvement of esophagitis with the use of pantoprazole 
or esomeprazole (88% in both treatments). And the num-
ber of patients with improvement of symptoms was also 
similar (50% and 47%), respectively18(A).
After four weeks of treatment, the number of pa-
tients who reported resolution of symptoms was similar 
in both treatments (pantoprazole  =  99% and esomepra-
zole = 98%)19(A).
ESOMEPRAZOLE (20 MG) VERSUS PANTOPRAZOLE (20 MG)
There is no difference between esomeprazole 20 mg and 
pantoprazole 20 mg in the treatment of patients with non-
erosive GERD regarding persistent symptom resolution at 
14 days (56.4% versus 54.4%) and 28 days (80 2% versus 
79.4%)20(A). 
ESOMEPRAZOLE (20/40 MG) VERSUS OMEPRAZOLE (20 MG)
The healing rates of esophagitis at eight weeks of treatment 
were similar between esomeprazole 20  mg (90.6%) and 
omeprazole 20 mg (88.3%)21(A).
The number of patients cured with esomeprazole 
40 mg compared to omeprazole 20 mg was similar at four 
weeks (71.5% versus 68.6%) and eight weeks (92.2% versus 
89.8%)22(A) .
After 4 and 8 weeks, respectively, of treatment in pa-
tients treated with esomeprazole 40  mg compared with 
omeprazole 20  mg, the improvement of esophagitis was 
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93.7% versus 81.7% (ARR: 12.0%; 95%  CI: 9 4%-14.6%; 
NNT: 8) and 84.2% versus 68.7% (ARR: 15.5%; 95% CI: 
12.1%-18.9%; NNT: 6)23(A).
A larger number of patients had resolution of esophagi-
tis with the use of esomeprazole 40 mg than with omepra-
zole 20 mg at four weeks (75.9% versus 64.7%; ARR: 7.3%; 
95%  CI: 4.0%-10.6%; NNT: 14) and eight weeks (94.1% 
versus 86.9%; ARR: 11.1%; 95% CI: 6.0%-16.2%; NNT: 9). 
And with the use of esomeprazole 20 mg, there was also 
a larger number of patients with resolution only at the 
4th week of treatment (70.5% versus 64.7%; ARR: 5.7%; 
95% CI: 0.4%-11.0%; NNT: 18)24(A).
Resolution of symptoms at four weeks was similar, re-
gardless of whether the treatment was esomeprazole 20 mg 
or 40 mg or omeprazole 20 mg25(A).
ESOMEPRAZOLE (40 MG) VERSUS LANSOPRAZOLE (30 MG)
The use of esomeprazole 40  mg was superior when 
compared to lansoprazole 30 mg in the resolution of re-
flux esophagitis, and the healing rate was 58.6% versus 
49.4% (ARR: 9.3%; 95%  CI: 3.0%-15.6%; NNT: 11) in 4 
weeks and 82.4% versus 77.5% (ARR: 15.0%; 95%  CI: 
14.5%-19.5%; NNT: 7) in 8 weeks26(A).
In patients with erosive esophagitis, the treatment 
with esomeprazole 40  mg is superior to lansoprazole 
30 mg, with a healing rate in four weeks of 79.4% versus 
75.1% (ARR: 4.3%; 95% CI: 2.0%-6.6%; NNT: 23), and in 
eight weeks of 92.6% versus 88.8% (ARR: 3.8%; 95% CI: 
2.2%-5.4%; NNT: 26)27(A).
PANTOPRAZOLE (40MG) VERSUS OMEPRAZOLE (40 MG)
The percentage of patients who had their esophagitis re-
solved with pantoprazole 40 mg and omeprazole 40 mg was 
equivalent, with 65.3% and 66.3% at 4-week treatment and 
84.3% and 84.9% at 8-week treatment, respectively28(A). 
After treatment with pantoprazole 20 mg or omepra-
zole 20 mg, the resolution rates of esophagitis were equiva-
lent, 77% versus 81% at 4-week treatment and 81% versus 
88% at 8-week treatment, respectively29(A).
In patients with erosive esophagitis, the treatment with 
pantoprazole 40  mg or omeprazole 20  mg is equivalent, 
with resolution rates of 74% and 78% at 4 weeks, respec-
tively, and 90% and 94% at 8 weeks, respectively30(A).
The improvement of heartburn in patients with ero-
sive reflux esophagitis is similar with either pantoprazole 
40 mg or omeprazole 20 mg and31(A).
RABEPRAZOLE (20 MG) VERSUS OMEPRAZOLE (20 MG)
In 4 and 8 weeks of treatment, the resolution of esopha-
gitis achieved with rabeprazole 20  mg or omeprazole 
20 mg is similar, with rates ranging from 81% for both 
treatments in 4 weeks and 92% versus 94% in 8 weeks, 
respectively32(A).
LANSOPRAZOLE (30 MG) VERSUS OMEPRAZOLE (20 MG) AND/OR 
VERSUS PANTOPRAZOLE (40 MG)
Regarding the improvement of heartburn at four or eight 
weeks, lansoprazole 30 mg is similar to omeprazole 20 mg 
and pantoprazole 40 mg31(A). 
There is no difference in heartburn resolution rates of 
patients with erosive esophagitis, when treated with lan-
soprazole 30 mg or omeprazole 20 mg for 4 weeks (77.2% 
versus 76.2%) or 8 weeks (84.3% versus 83.0%)33(A). 
The esophagitis resolution rates at 4 and 8 weeks were 
equivalent, 70% and 87%, respectively, with lansoprazole; 
and 63% and 82%, respectively, with omeprazole34(A).
RABEPRAZOLE (10 MG) VERSUS ESOMEPRAZOLE (20 MG)
The time required for 24 hours free of heartburn and re-
gurgitation symptoms is similar with the use of rabepra-
zole 10 mg or esomeprazole 20 mg for treatment of non-
erosive GERD. Also with regard to global improvement of 
symptoms reported by patients, both forms of treatment 
have similar results (96% versus 87.9% - NS)35(A).
RECOMMENDATIONS 
Esomeprazole 20/40 mg, lansoprazole 30 mg, omeprazole 
20/40 mg, pantoprazole 40 mg, and rabeprazole 20 mg are 
equivalent for treating patients with erosive GERD. 
Esomeprazole 20/40 mg, omeprazole 20 mg, pantopra-
zole 20 mg, and rabeprazole 10 mg are equivalent for treat-
ing patients with non-erosive GERD. 
4. ARE THERE DIFFERENCES IN THE TREATMENT OF EROSIVE 
AND NON-EROSIVE GERD?
ESOMEPRAZOLE
In patients with erosive GERD, the six-month mainte-
nance treatment with esomeprazole 40  mg, 20  mg, or 
10  mg reduced the risk of treatment discontinuation 
in 59.5% (95%  CI: 48.9-70.1; NNT: 2), 52.6% (95%  CI: 
41.1-64.1; NNT: 2), and 30.8% (95% CI: 17.1-44.5; NNT: 3), 
respectively. It also reduced the risk of persistent esoph-
agitis in 51.8% (95%  CI: 40-60.3; NNT: 2) and 43.4% 
(95% CI: 30.8-56; NNT: 2) at doses of 40 mg and 20 mg, 
respectively. With regard to heartburn, analysis by in-
tention to treat (ITT) shows reduced risk of symptoms 
in 44.8% (95%  CI: 32.8-56.8; NNT: 2), 38.3% (95%  CI: 
26.5-50.1; NNT: 3), and 21.3% (95% CI: 9.7-32.9; NNT: 5) 
at doses of 40 mg, 20 mg, and 10 mg, respectively36(A). 
In patients with erosive GERD, the use of esomepra-
zole 40 mg, 20 mg, or 10 mg for six months reduced the 
risk of persistent esophagitis in 63.2% (95%  CI: 52-75.2; 
NNT: 2), 63.2% (95%  CI: 52-75.2; NNT: 2), and 27.2% 
(95% CI: 12.1-42.3; NNT: 4), respectively. It also reduced 
the risk of discontinuing treatment in 59.7% (95%  CI: 
46.2-71.2; NNT: 2), 67.2% (95%  CI: 55.7-78.7; NNT: 2), 
respectively37(A).
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In patients with non-erosive GERD, night-time heart-
burn was treated in 53.1% (111/209), 50.5% (111/220), 
and 12.7% (28/221) of the patients who received esome-
prazole 40 mg, 20 mg, and placebo, respectively. The dif-
ference between esomeprazole 40 mg and 20 mg versus 
placebo was 40.5% (95%  CI: 32.4%, 48.5%) and 37.8% 
(95%  CI: 29.9%, 45.7%), respectively, with NNT of 2 
in both treatments. The sleep disorders associated with 
GERD were significantly more resolved in patients who 
received esomeprazole 40 mg (73.7%) or 20 mg (73.2%) 
than placebo (41.2%), with risk reduction of 32.5% 
(NNT: 3) and 32.0% (NNT: 3), respectively6(A).
During 6 months follow-up, the proportion of pa-
tients with non-erosive GERD who discontinued treat-
ment due to insufficient control of heartburn was signifi-
cantly lower among patients treated with esomeprazole 
20 mg (14%) than placebo (51%), with difference of 37% 
(95% CI: 7.7-24.7; NNT: 3)38(A).
Treatment of patients with non-erosive GERD with 
esomeprazole 40  mg or 20  mg provides a reduced risk 
of heartburn at 4 weeks, ranging from 18.8% (95%  CI: 
8.5-29.1) to 24.5% (95% CI: 14.0-35.0; NNT: 4 or 5) 
with 40 mg; and from 20.2% (95% CI: 9.8-30.6) to 29.7% 
(95% CI: 18.9-40.5 95; NNT: 3 or 5) with 20 mg7(A).
The overall result (erosive  =  240 and non-erosive 
GERD = 114) of response to treatment with esomepra-
zole 40 mg and 20 mg for 12 days shows that the risk of 
persistent heartburn had a reduction of 38.1% (95% CI: 
26.4-49.8; NNT: 3) and 40.3% (95% CI: 28.6-52.0; NNT: 2), 
respectively. And patients with erosive GERD had a 
greater benefit than patients without erosion, reducing 
the risk of treatment failure in 13.3% (95% CI: 3.3-23.3; 
NNT: 8)8(A).
LANSOPRAZOLE
Data on daily records of patients with non-erosive GERD 
indicate that after 8 weeks of treatment with lansoprazole 
30 mg or 15 mg the persistence of night-time heartburn 
was present in 49% and 39% of patients, respectively. 
Compared with placebo, there was reduced risk for 
the presence of night-time heartburn in 19.3% (95% CI: 
2.0-36.6; NNT: 5) and 29.2% (95% CI: 11.9-46.5; NNT: 
4), respectively. Similarly, daytime heartburn reduction 
with the use of 30  mg and 15  mg was 19.3% (95%  CI: 
3.6-35.0; NNT: 5) and 24.6% (95% CI: 8.5-40.7; NNT: 4), 
respectively9(A).
OMEPRAZOLE
The proportion of patients with erosive GERD who 
maintained resolution of esophagitis after six months 
was 43.3% with omeprazole 20  mg, 10  mg 39.7%, and 
0% for placebo. The number needed to treat is 2 for both 
doses10(A).
Recurrence of esophagitis in 18 months is 40% with 
omeprazole 10 mg and 85% with placebo, with the signif-
icant difference of 45% (95% CI: 34.6-55.4; NNT: 2). Re-
garding the persistence of symptoms, there is no differ-
ence between omeprazole (53%) and placebo (56%)39(A).
The reduced risk of heartburn after 6 months tak-
ing omeprazole 20  mg or 10  mg was 27.6% (95%  CI: 
17.4-37.8; NNT: 4) and 13.8% (95% CI: 2.7-24.9; NNT: 7), 
respectively, in patients with non-erosive GERD40(A).
At 24 weeks of treatment with omeprazole 10  mg, 
patients with non-erosive GERD have reduced risk of 
treatment discontinuation of 24.9% (95% CI: 16.6-33.2; 
NNT: 4), persistent heartburn of 28.8% (95%  CI: 
20.9-36.7; NNT: 3) and recurrence of symptoms of 28.4% 
(95% CI: 20.5-36.3; NNT: 4)41(A).
In patients with GERD treated with omeprazole 
20 mg for 4 weeks, there is a reduction in the risk of per-
sistent heartburn in 38.2% (95% CI: 26.0-50.4 95; NNT: 3) 
and regurgitation in 28.7% (95%  CI: 16.1-41.3; NNT: 
3)42(A).
The treatment failure rate was lower in patients with 
non-erosive GERD treated with omeprazole 20 mg. The 
reduction in risk of treatment failure at 4 and 8 weeks is 
53.2% (95% CI: 44.0-62.4; NNT: 2) and 46.2% (95% CI: 
36.5-55.9; NNT: 2), respectively11(A).
The 4-week treatment of patients with non-erosive 
GERD receiving omeprazole 20  mg resulted in a re-
duced risk of persistent heartburn and dissatisfaction of 
33.0% (95% CI: 23.6-42.4; NNT: 3) and 34.0% (95% CI: 
23.9-45.9; NNT: 3), respectively. With the use of omepra-
zole 10 mg, the reduction was 17.9% (95% CI: 8.8-27.0; 
NNT: 6) and 25.9% (95% CI: 14.7-37.1; NNT 4), respec-
tively12(A). 
PANTOPRAZOLE
The resolution rates of esophagitis at 4 weeks were 42%, 
55%, and 72% with the use of pantoprazole 10 mg, 20 mg 
and 40  mg, respectively, compared to placebo it pro-
duces a risk reduction of esophagitis in 27.4% (95% CI: 
16.8-38.0; NNT: 4), 40.6% (95% CI: 30.0-51.2; NNT: 2), 
and 57.7% (95% CI: 47.6-67.8; NNT: 2), respectively. Risk 
reduction of esophagitis at 8 weeks was 26.3% (95% CI: 
13.8-38.8; NNT: 4), 45.3% (95% CI: 33.4-57.2; NNT: 2), 
and 55.5% (95% CI: 44.3-66.7; NNT: 2), with pantopra-
zole 10  mg, 20  mg, and 40  mg, respectively. Persistence 
of morning and daytime heartburn in patients treated with 
pantoprazole 40 mg at 8 weeks was 21.0% and 18.0%, re-
spectively, and risk reduction was 49.9% (95% CI: 38.3-61.5; 
NNT: 2) for morning and 26.0% (95% CI: 13.8-38.2; NNT: 
4) for night-time13(A).
In patients with reflux esophagitis treated with PPI, 
the six-month maintenance treatment with pantopra-
zole 20 mg reduced the risk of esophagitis recurrence in 
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38.5% (95% CI: 21.4-55.6; NNT: 3) and incidence of re-
flux symptoms in 45.5% (95% CI: 28.6-62.4; NNT:2)43(A).
Maintenance treatment of patients with non-erosive 
GERD for 6 months with pantoprazole 20  mg reduced 
the risk of treatment discontinuation in 15.1% (95%  CI: 
8.9-21.3; NNT: 7)44(A).
RABEPRAZOLE
In patients with reflux esophagitis, treatment with rabe-
prazole 10 mg and 20 mg reduced the risk of treatment 
discontinuation in 45.7% (95%  CI: 31.2-60.2; NNT: 2) 
and 58.5 % (95%  CI: 45.8-71.2; NNT: 2), respectively; 
recurrence of esophagitis in 45.7% (95%  CI: 31.0-60.4; 
NNT: 2) and 64.1% (95%  CI: 51.5-76.7; NNT: 2), re-
spectively; and persistent symptoms in 51.4% (95%  CI: 
37.7-65.1; NNT: 2) and 59.6% (95% CI: 46.5-72.7; NNT: 
2), respectively45(A).
In patients with reflux esophagitis, the one-year treat-
ment with rabeprazole 10  mg or 20  mg produced a risk 
reduction of treatment discontinuation in 55.9% (95% CI: 
44.3-67.5; NNT: 2) and 64.2% (95% CI: 53.8-74.6; NNT: 
2), respectively; esophagitis recurrence in 62.7% (95% CI: 
51.7-73.7; NNT: 2) and 71.0% (95% CI: 61.1-80.9; NNT: 1), 
respectively; and heartburn recurrence in 41.2% (95% CI: 
28.4-54.0; NNT: 2) and 51.5 % (95%  CI: 39.5-63.5; 
NNT: 2), respectively46(A).
In patients with GERD, the use of rabeprazole 20 mg 
for 4 weeks reduced the risk of persistent heartburn in 
28.6% (95%  CI: 18.9-38.3; NNT: 3) and regurgitation 
in 35.2% (95% CI: 21.7-48.7; NNT: 3)47(A).
During the 6-month treatment of non-erosive GERD 
patients with the use of rabeprazole 10  mg, there was 
a reduced risk of discontinuation of 14.4% (95%  CI: 
7.2-21.6; NNT: 7) and inadequate symptom control of 
11.2% (95% CI: 2.6-19.8; NNT: 948(A).
The 4-week treatment in patients with non-erosive 
GERD receiving rabeprazole 10 mg or 20 mg produced a 
risk reduction of persistent heartburn in 25.2% (95%  CI: 
13.5-36.9; NNT: 4) and 25.5% (95% CI: 14.0-37.0; NNT: 4), 
respectively, and reduced the risk of dissatisfaction with the 
level of symptom improvement in 23.8% (95% CI: 7.3-40.3; 
NNT: 4) and 24.3% (95% CI: 8.0-40.6; NNT: 4)15(A).
RECOMMENDATIONS
In patients with erosive and non-erosive GERD, the use of 
esomeprazole at doses of 20 mg and 40 mg brings benefit 
to heartburn, with NNT ranging between 2 and 3. Patients 
with erosive GERD have a lower treatment failure (NNT: 
8). In patients with erosive GERD, the use of esomepra-
zole in doses of 20 mg and 40 mg brings benefits regarding 
treatment discontinuation outcomes, reduction of esopha-
gitis and heartburn, with NNT ranging from 2 to 5. In pa-
tients with non-erosive GERD, the use of esomeprazole in 
doses of 20 mg and 40 mg brings benefits regarding treat-
ment discontinuation outcomes, reduction of sleep disor-
ders and heartburn, with NNT ranging from 2 to 5.
In patients with non-erosive GERD, the use of lanso-
prazole in doses of 15 mg and 30 mg produces a reduction 
in heartburn (daytime or night-time), with NNT ranging 
from 4 to 5. 
In patients with erosive GERD, the use of omepra-
zole in doses of 10 mg and 20 mg brings benefit regarding 
esophagitis resolution outcomes and reduction of recur-
rence, with NNT of 2.
In patients with non-erosive GERD, the use of omepra-
zole in doses of 10 mg and 20 mg brings benefit regard-
ing the outcomes of heartburn, regurgitation, treatment 
discontinuation, reduction of symptoms recurrence, and 
treatment failure, with NNT ranging from 2 to 7.
In patients with erosive GERD, the use of pantopra-
zole in doses of 10 and 20 mg brings benefit regarding the 
resolution of esophagitis, reduction of recurrence, with 
NNT of 2. In patients with non erosive GERD, the use of 
pantoprazole in doses of 10 mg and 20 mg brigs benefit 
regarding the outcomes of heartburn, regurgitation, treat-
ment discontinuation, decrease of symptoms recurrence 
and therapeutic failure, with NNT ranging from 2 and 7.
In patients with erosive GERD, the use of rabepra-
zole in doses of 10 mg and 20 mg brings benefit regarding 
the outcomes of treatment discontinuation, resolution of 
esophagitis, heartburn, and reduction of recurrence, with 
NNT ranging from 1 and 2. In patients with erosive GERD, 
the use of rabeprazole in doses of 10 mg and 20 mg brings 
benefit regarding the outcomes of treatment discontinu-
ation, control of heartburn and regurgitation symptoms, 
with NNT ranging from 2 to 9.
5. SHOULD PROTON PUMP INHIBITOR IN GERD PATIENTS 
BE USED IN ONE OU TWO DAILY DOSES? 
In patients with erosive GERD, the use of rabeprazole 
10 mg in two daily doses for 8 weeks compared to rabepra-
zole 20 mg once daily did not increase the number of pa-
tients with improvement at endoscopic examination and, 
moreover, it increases the symptom severity on day 3 of 
treatment49(A).
Response to treatment of patients diagnosed with 
GERD by esophageal pH-metry and upper digestive en-
doscopy, with esomeprazole 20  mg (twice daily) and 
40 mg (once daily) for two weeks, is similar, 79% and 86%, 
respectively4(A).
The overall response result (erosive GERD = 240 pa-
tients and non-erosive GERD = 114 patients) to treatment 
with esomeprazole 40 mg once daily and 20 mg twice daily 
for 12 days is similar. There is no difference in healing and 
symptom response when patients with GERD (erosive 
and non-erosive) are analyzed separately8(A).
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RECOMMENDATION
In patients with GERD (erosive and non-erosive) there is 
no difference in clinical response to treatment with pro-
ton pump inhibitor in two daily doses compared to one 
daily dose.
6. SHOULD PROTON PUMP INHIBITOR MAINTENANCE IN 
NON-EROSIVE GERD BE USED CONTINUOUSLY, INTERMIT-
TENTLY, OR ON-DEMAND?
In patients with non-erosive GERD, the use of esome-
prazole 20  mg on-demand compared with lansoprazole 
15 mg continuous treatment (once daily) reduced the risk 
of treatment discontinuation (due to lack of improvement) 
in 7% (NNT: 14) and adverse effects (headache and diar-
rhea) in 6.4% (NNT: 16)50(A).
In patients with GERD symptoms, the 4-week treat-
ment with esomeprazole 20  mg daily on-demand com-
pared to intermittent treatment with esomeprazole 40 mg 
daily did not increase the degree of patient satisfaction, but 
reduced the number of symptom relapses at 6 months51(A).
RECOMMENDATION
The use of esomeprazole (20  mg/day) on-demand for 6 
months reduces treatment discontinuation (NNT: 14), 
number of relapses (NNT: 1), and number of adverse ef-
fects (headache and diarrhea) (NNT: 16), compared to 
continuous treatment with lansoprazole 15 mg/day or in-
termittent with esomeprazole 40 mg/day.
7. SHOULD HISTAMINE TYPE-2 RECEPTOR BE ASSOCIATED 
WITH PROTON PUMP INHIBITOR IN GERD TREATMENT?
The percentage of time with pH > 4 overnight was 51% in 
PPI group (omeprazole 20 mg or lansoprazole 30 mg twice 
daily), compared to 96% in H2 blocker group (ranitidine 
300 mg, 40 mg famotidine, or nizatidine 300 mg) noctur-
nal (p < 0.0001). Nocturnal acid episodes occurred in 82% 
of patients who received only PPI52(B). 
Night-time use of ranitidine (150  mg) after a week 
of omeprazole 40  mg resulted in a significant reduction 
(p  <  0.01) in the percentage of time intragastric pH  <  4 
compared to placebo53(B).
Addition of low-dose ranitidine (75 mg) helps to con-
trol nocturnal gastric acidity, which may occur in standard 
administration of omeprazole54(B).
Addition of H2 blocker led to improvement symptoms 
in 72% of patients (28/39), nocturnal reflux symptoms in 
74% of patients (25/34), and sleep disorders in 67% of pa-
tients (18/27)55(B).
Administration of PPI (omeprazole 40 mg) + H2 block-
er (ranitidine 300  mg) at day 1 significantly reduces the 
percentage of time gastric pH  <  4 for the supine period 
compared to PPI alone (omeprazole 40 mg) (p < 0.001). 
There is no difference at one and two weeks or 30 days56(B).
Association with ranitidine at night minimizes time 
percentage with pH < 4 when compared to omeprazole 
20 mg, in 5% when administered ranitidine 150 mg and 
6% when ranitidine 300  mg (p  <  0.01 vs. omeprazole 
20 mg bid and 20 mg at night)57(B).
The average value for percentage of time intragrastric 
pH < 4 in supine position with omeprazole 20 mg twice 
daily was 18.9 compared to 29.7 with omeprazole + ra-
nitidine 150 mg (p = 0.003)58(B).
RECOMMENDATION
The night-time association of ranitidine with PPI helps 
control gastric acidity, improving reflux symptoms and 
sleep problems.
8. SHOULD PROKINECT BE ASSOCIATED WITH PROTON 
PUMB INHIBITOR IN GERD TREATMENT?
In asthmatic patients with GERD diagnosed by pH-
metry, after antireflux therapy (omeprazole 20  mg bid 
+ domperidone 10  mg tid) compared with placebo 
(p  <  0.001) there was significant reduction in daytime 
asthma (17.4% versus 8.9%), night-time asthma (19.6% 
versus 5.4%), and reflux (8.7% versus 1.6% ) symptom 
scores and use of rescue medication (23.2% versus 
3.1%)59(A).
In patients with heartburn and/or regurgitation 
symptoms, there is no difference in symptom response 
to therapy with pantoprazole 40  mg bid compared to 
the association with mosapride 5 mg tid (69.7% versus 
89.2%, respectively, p = 0.11). The symptom score after 
8 weeks was significantly lower in patients who used the 
association (3.78 ± 3.62 versus 1.67 ± 2.09, p = 0.009). In 
patients with non-erosive GERD there was no significant 
difference between the two types of therapy (pantopra-
zole 17/20 and pantoprazole + mosapride 7/9, p = 0.63). 
In erosive esophagitis, the symptomatic response oc-
curred more often with the association (18/19, 94.7%) 
than with pantoprazole alone (6/13, 46.2%, p = 0.003). 
However, the resolution of endoscopic esophagitis was 
similar in both regimens (pantoprazole 6/11, 54.5% and 
association 12/17, 70.5%)60(A).
In patients with erosive GERD, grades II or III, af-
ter 4 and 8 weeks of treatment with pantoprazole 40 mg 
or pantoprazole 40  mg + 20  mg cisapride, there was 
no difference in resolution endoscopy at 4 weeks (81% 
and 82% , respectively) and at 8 weeks (89% and 90%, 
respectively)61(A). 
The number of patients who maintained symptom 
remission at 12 months follow-up were 28 of 35 (80%) 
with omeprazole 20  mg/day and 31 of 35 (89% with 
omeprazole + cisapride 30 mg/day). Combination ther-
apy with omeprazole + cisapride was significantly more 
effective than cisapride alone (p = 0.003)62(A).
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RECOMMENDATION 
In patients with GERD, erosive or non-erosive, the benefit 
of prokinetic and proton pump inhibitor association is con-
troversial. Moreover, the main prokinetics available in our 
area (domperidone, metoclopramide, bromopride) have 
not been consistently studied regarding its use in combina-
tion with PPIs in these patients.
9. CAN CHRONIC USE OF PROTON PUMP INHIBITOR CAUSE GAS-
TRIC DISEASE?
At one-year treatment with omeprazole 40  mg daily, the 
prevalence of parietal cell protrusion increases from 18% to 
86% (p < 0.001), unrelated with the eradication of Helico-
bacter pylori (HP). However, the prevalence of fundic gland 
cysts increases from 8% to 35% (p < 0.05), being more prev-
alent in patients undergoing HP eradication (p < 0.05)63(A).
At 7 years treatment, patients with GERD who remained 
HP negative showed no histological signs of gastric disease. 
In HP positive patients, the use of omeprazole 20 mg for 7 
years produced glandular atrophy, which was not observed 
in patients undergoing surgery64(A).
In GERD patients with HP positive, the chronic use of 
omeprazole 20  mg for 5 years increased enterochromaffin 
cell hyperplasia of the oxyntic mucosa, compared to the use 
of robeprazol 10 mg or 20 mg65(A). 
In patients receiving 40 mg of omeprazole for 2 years, in 
whom eradication of HP was not effective, the same signs 
of chronic gastritis occurred (argyrophilic cell hyperplasia 
and atrophy), compared to patients with only chronic use of 
omeprazole 40  mg. In contrast, patients who remained HP 
negative using omeprazole 40 mg had the same histological re-
covery found in patients who had successful eradication66(A). 
In GERD patients with HP positive, the use of omepra-
zole 40 mg for one-year determined a pattern of gastric antral 
mucosa atrophy compared to patients who underwent HP 
eradication67(A). 
GERD patients infected with HP have more gastric mu-
cosa atrophy than HP negative patients, and this histologi-
cal change progresses over 3 years of treatment. However, 
in these patients, there is no difference in changes of gastric 
atrophy when comparing treatment with omeprazole 20 mg 
and 40 mg with surgical treatment68(A).
RECOMMENDATION 
Chronic use of omeprazole increases the prevalence of gas-
tric atrophy signs over the years, particularly when associ-
ated with HP, noting that HP eradication produces changes 
in fundic glands
10. SHOULD HELICOBACTER PYLORI BE ERRADICATED IN 
CHRONIC USE OF PROTON PUMP INHIBITOR? SHOULD HELI-
COBACTER PYLORI BE TREATED IN PATIENTS WITH GERD?
In patients with GERD after one year follow-up, the prob-
ability of treatment failure (GERD symptoms) is higher 
in HP-eradicated patients (43.2%) than in non-eradicated 
patients (21.1%)69(A).
In patients with GERD, HP eradication with amoxi-
cillin 2.0 g/day and clarithromycin 1.0 g/day reaches lev-
els of 88%, with 2 years of decrease in gastric inflamma-
tion, although it does not change the need for chronic 
use of omeprazole 40 mg/day or the presence of GERD 
symptoms66(A).
The recurrence rate of GERD symptoms in one-
year is not different in patients undergoing or not HP-
eradication70(A). 
Over one-year period of GERD treatment with 
omeprazole 40  mg/day, the chronic inflammation signs 
are reduced compared to non-eradicated HP patients67(A). 
At six months follow-up, the presence of pH influ-
enced the recurrence rates of GERD symptoms. Eradica-
tion prolongs the disease-free interval71(A).
RECOMMENDATION 
In the long-term (more than one year), HP eradication 
in GERD patients does not reduce the presence of symp-
toms or recurrence rates, although it reduces the histo-
logical signs of gastric inflammation. 
11. HOW LONG IS THE TREATMENT AND WHAT IS THE 
DOSE OF PROTON PUMP INHIBITOR IN GERD PATIENTS 
WITH ATIPICAL MANIFESTATIONS?
ASTHMA
In asthma, pantoprazole 40 mg once daily for 3 months 
does not improve symptoms and lung function; although 
it improves quality of life scores72(A).
Pantoprazole 40 mg once daily for 3 months does not 
improve symptom and reflux scores and does not reduce 
the number of patients with change in esophageal pH-
metry73(A).
In asthmatic patients, lansoprazole 30 mg twice daily 
for 6 months reduces the risk of symptom exacerbation 
(NNT: 8)74(A).
LARYNGITIS
In patients with laryngitis, the use of esomeprazole 40 mg 
once daily for 4 months does not improve quality of life 
scores, symptoms, and GERD scores75(A).
In laryngitis, lansoprazole 30  mg twice daily for 3 
months improves symptoms of GERD (NNT: 2)76(A).
CHRONIC COUGH
Lansoprazole 30 mg once daily compared to twice daily 
for 3 months did not improve GERD symptoms and VAS 
scale, and does not reduce the number of patients with 
symptoms77(A).
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BRONCHIAL HYPERREACTIVITY
The use of omeprazole 40  mg twice daily for 3 months 
reduces the risk of heartburn (NNT: 2) and time pH < 4 
at the esophageal pH-metry examination78(A).
NON-CARDIAC CHEST PAIN
The use of omeprazole 20 mg twice daily for 2 months in-
creases the likelihood of symptom improvement (NNT: 1) 
and reduces pain score and number of days with 
pain79(A).
RECOMMENDATION
In patients with atypical symptoms (asthma, bronchial 
hyperreactivity, laryngitis, and non-cardiac chest pain), 
there is benefit with the use of double-dose PPI for 2 to 6 
months (NNT: 1-8).
12. ARE PROTON-PUMP INHIBITORS DIFFERENT IN THE 
RESPONSE OF TREATED GERD MAINTENANCE THERAPY?
PANTOPRAZOLE 20 MG VERSUS ESOMEPRAZOLE 20 MG
In 6 months of erosive GERD maintenance treatment, 
pantoprazole 20  mg and esomeprazole 20  mg have the 
same remission rate of symptoms and esophagitis (84% 
and 85%, respectively)80(B).
At 6 months follow-up, the percentage of patients 
who remain with esophagitis resolution is greater with 
esomeprazole 20 mg than with lansoprazole 20 mg (87% 
versus 74.9%; ARR: 12.1%; 95% CI: 9.2%-15%; NNT: 8); 
NNT: 12, 8, 6, and 10 for grades A, B, C and D, respec-
tively (Los Angeles classification)81(A).
LANSOPRAZOLE 15 MG VERSUS ESOMEPRAZOLE 20 MG
The number of patients treated for erosive GERD with 
maintenance endoscopic remission is greater in those 
who received esomeprazole 20  mg for 6 months than 
in those who received lansoprazole 15  mg (84.8% 
versus 75.8%; ARR: 9.0%; 95%  CI: 4.1%-13.9%; NNT: 
11), although there is no difference between the presence 
of heartburn (23.6% versus 26.2% – NS) and regurgita-
tion (20% in both regimes)82(B). 
In 6 months of follow-up, esomeprazole 20 mg has a 
greater proportion of patients who remain with esophagi-
tis resolution than lansoprazole 20 mg (87% versus 74.9% - 
ARR: 12.1%; (95% CI: 9.2%-15%) – NNT: 8 (NNT 12, 8, 
6, and 10 for the degrees [Los Angeles classification] A, B, 
C, and D, respectively)81(A).
In 6 months treatment, esomeprazole 20  mg has a 
greater proportion of patients in remission than lanso-
prazole 15 mg (83% versus 74%, respectively; RRA: 9%; 
95% CI: 4.4%-13.6%; NNT: 11)83(A).
RABEPRAZOLE 10 MG VERSUS OMEPRAZOLE 20 MG
The use of rabeprazole 10 mg and 20 mg was equivalent to 
omeprazole 20 mg in the maintenance of esophagitis reso-
lution at 52 weeks84(A).
LANSOPRAZOL 30 MG VERSUS OMEPRAZOL 20 MG
Only 3.7% and 5% of patients with erosive GERD treated 
with lansoprazole and omeprazole, respectively, had treat-
ment failure at 6 months follow-up85(A).
There is no difference between the two forms of treat-
ment regarding the proportion of patients with recurrence 
of esophagitis (symptoms and/or endoscopy): lansopra-
zole (9.5%) and omeprazole (9%)86(A).
RECOMMENDATION
Esomeprazole 20  mg, lansoprazole 30  mg, omeprazole 
20  mg, pantoprazole 20  mg, and rabeprazole 10  mg are 
equivalent in the maintenance treatment of patients with 
erosive GERD.
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